Eighteen years of qualification
Audited Supplier
In This Store
Founded in 1985, Sichuan YuandaShuyangPharmaceutical Co., Ltd. (SYSP) was an army-owned enterprise. In 1998, SYSP was take over by Chengdu municipal government, In 2001 China Grand Enterprises wholly purchased SYSP and restructured it into a joint-stock enterprise in 2007.
SYSP has total assets of RMB 1.1 billion and its manufacturing base is located in high-tech zone of Chengdu city. Besides, SYSP also has 13 plasmapheresis-stations in Sichuan and Guangxi province. SYSP’S average annual sales revenue is above RMB 600million and profit tax over 80 million per year. Its sales network covers both domestic and abroad market. SYSP is the first batch of blood products manufacturer which passed both GMP and ISO 9001 quality certification. SYSP is also the first one which simultaneously passed verification of quality, environment, and careers and received export certification from Russia and Turkey etc. SYSP is specialize in manufacture and sale of 8 different products in 23 specifications, including Human Albumin, Human Immunoglobulin for Intravenous Injection (PH4), Human Hepatitis B Immunoglobulin for Intravenous Injection(PH4), Human Hepatitis B Immunoglobulin ,Human Tetanus Immunoglobulin, Human Rabies Immunoglobulin and Human Histamine Immunoglobulin. The exclusive-owned technology of double inactivation of virus without protectant has gained USA, Australia and China patent. In June 2008, Human hepatitis B immunoglobulin for intravenous injection (PH4) was firstly manufactured and introduced to market by SYSP in Asia .Hence, SYSP was honored with the first prize of science and technology development in Sichuan province and the prize of outstanding science contribution to Chengdu city.
At present, SYSP has become one of the most powerful blood products manufacturers in china and ranked top 50 industrial enterprises in Sichuan, top 20 industrial enterprises in Chengdu. SYSP is also recognized as “provincial Key Enterprises” and awarded “the top 30 enterprises of industrial pharmaceutical enterprises in Sichuan”
Year of Establishment: 1985
Total Assets(USD): More than 1000,000,000
Total Number of Staff: more than 500
Main Competitive Advantages:
Other Competitive Advantages: The company now employs more than 400 people and all the senior executives have acquired their senior technical titles. It has modern GMP-compliant workshops with a usable area of 6,000 square meters, and various advanced manufacturing equipment and test apparatus imported from countries including the U.S.A., Germany and Japan, which have provided technical assurance for the quality of the existing products and the R&D of new products.The company passed the acceptance inspection of China Certification Committee for Quality Mark and obtained ISO9001 Quality System Certificate. The quantity and quality of its leading products including Human Albumin and Human Immunoglobulin head the list of domestic blood product manufacturers, and its products are well sold in 30 domestic provinces, municipalities and autonomous regions, and some of them have successfully entered the international market.
Patents and Copyrights: The ‘preservative-free dual viral inactivation process’ developed and invented independently by the company has obtained a patent certificate issued by the United States Patent and Trademark Office, with Patent No. US006338849B1, a patent certificate issued by IP Australia, with Patent No. 756017, and a patent certificate issued by the State Intellectual Property Office of P. R. China, with Patent No. ZL98112108.X.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us：
Pharma Sources Insight JANUARY 2024
